A. Rachel Leheny
Known title: Chief Executive OfficerCIK: 0001484729
A. Rachel Leheny's purchase track record
How the stock did after each of A. Rachel Leheny's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 7 since May 16, 2023
Stock higher 6 months later
50%
3 months: 50%
Median 6-month return
+26.2%
3 months: +10.5%
Beat the S&P 500
50%
median +17.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/14/2025 | CALC | $10K | +40.5% | +132.8% | +11.3% |
| 11/1/2024 | CALC | $75K | -27.1% | -50.1% | -0.7% |
| 8/27/2024 | CALC | $4K | -19.5% | -48.9% | +5.9% |
| 11/3/2023 | CALC | $29K | +95.8% | +101.4% | +17.6% |
| 6/8/2023 | CALC | $7K | pending | pending | — |
| 5/31/2023 | CALC | $19K | pending | pending | — |
| 5/16/2023 | CALC | $13K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CALC | ▲ Buy | Grant | 186,729 | $150K | 6/25/2026 | View on chart |
| CALC | ▲ Buy | Open Market | 1,000 | $3K | 7/21/2025 | View on chart |
| CALC | ▲ Buy | Open Market | 2,500 | $6K | 7/14/2025 | View on chart |
| CALC | ▲ Buy | Open Market | 20,000 | $75K | 11/1/2024 | View on chart |
| CALC | ▲ Buy | Open Market | 1,000 | $4K | 8/27/2024 | View on chart |
| CALC | ▲ Buy | Grant | 91,086 | $389K | 1/23/2024 | View on chart |
| CALC | ▲ Buy | Open Market | 2,000 | $7K | 11/7/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 2,440 | $8K | 11/6/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 5,000 | $14K | 11/3/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 400 | $2K | 6/9/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 928 | $5K | 6/8/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 1,000 | $5K | 6/7/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 1,000 | $5K | 6/6/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 1,000 | $5K | 6/2/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 1,000 | $4K | 5/31/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 3,000 | $10K | 5/23/2023 | View on chart |
| CALC | ▲ Buy | Open Market | 1,000 | $3K | 5/16/2023 | View on chart |
| CALC | ▲ Buy | Grant | 356,989 | — | 3/20/2023 | View on chart |
| CALC | ▲ Buy | Grant | 66,228 | — | 3/20/2023 | View on chart |
| CALC | ▲ Buy | Grant | 316,109 | — | 3/20/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
CALC files prospectus supplement for $25M ATM offering
CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.
CALC files prospectus supplement for $25M ATM offering. CalciMedica has filed a prospectus supplement to conduct an at‑the‑market offering of up to $25 million of common stock. The filing indicates the company is seeking additional capital through a public offering. The stock currently trades near its $0.59 support level, and the neutral RSI suggests no strong momentum at present. The raise could provide funding for operations but may also dilute existing shareholders.